2 completed, 1 unknown, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Unknown 1, Withdrawn 1 |
Follow Attgeno AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery PDNO, Sodium chloride (placebo) - Pulmonary Hypertension | Phase 2 | Unknown | Attgeno AB | 12 | 2022-10-23 | 2023-08-01 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension Sodium chloride (placebo), PDNO - Pulmonary Hypertension, COVID-19 | Phase 1 / Phase 2 | Withdrawn | Attgeno AB | 2021-05-07 | 2023-08-01 | |
| A First-in-Human Study to Assess the Safety and Tolerability of PDNO PDNO, Sodium chloride (placebo) - Pulmonary Hypertension | Phase 1 | Completed | Attgeno AB | 38 | 2021-02-02 | 2023-01-19 |
| The Prevalence of Pulmonary Hypertension in Patients With COVID-19. Hypertension, Pulmonary, Right Ventricular Overload | Completed | Attgeno AB | 67 | 2020-06-01 | 2021-01-11 |
Hypertension, Pulmonary (4) · COVID-19 (1)
1-(nitrosooxy)propan-2-ol and 2-(nitrosooxy)propan-1-ol drug combination (3) · Sodium Chloride (3)
Sweden (4)